Clinical

RBM20 truncating variants are associated with a milder, lower-penetrance form of dilated cardiomyopathy compared with other pathogenic genetic drive.

Consistent adherence to sodium-glucose cotransporter 2 (SGLT2) inhibitors in individuals with type 2 diabetes reduces the risk of hospitalization, supporting targeted interventions to improve medication-taking behavior.

Digitalis glycosides lowered worsening heart failure events in patients with HFmrEF and HFrEF, but no mortality benefit was observed.

Circulating tumor DNA (ctDNA) detection is linked to worse survival outcomes in resectable melanoma, but high false-negative rates limit its use in surveillance or de-escalation.

Endometriosis increases ovarian cancer risk, but endometriosis-associated ovarian cancer shows favorable tumor characteristics and better survival.

Younger patients with early-onset CRC, especially men and racial and ethnic minority groups in urban areas, face a higher risk of cardiovascular death.

Eighteen Legionella cases were linked to Kaiser Santa Clara as officials investigate the source and infection risks.

The FDA announcement seeks nominees from the public for drug repurposing, leveraging AI signals to expand treatment options for rare diseases and other unmet needs.

In part 2, Deborah Doroshow, MD, PhD, discusses early clinical trial access, emerging lung cancer therapies, and barriers to equitable access.

Across a landmark guideline update, a primary prevention trial, and the first treat-to-target proof of concept, the message is consistent: lower LDL for longer saves lives—and achieving that goal in practice demands goals, teams, tools, and lifestyle as the foundation.

Even with a treat-to-target protocol, only 61% of Ez-PAVE participants reached goal—but the trial's broader lesson is that combination therapy and equitable access to newer agents are the path to closing the gap.

Welcome back to another AJMC Insights series. In this episode titled, ‘Addressing the Challenges of Undiagnosed Chronic Kidney Disease’, Manisha Jhamb led the conversation

Efgartigimod has recently been shown effective when investigated to treat ocular myasthenia gravis and juvenile myasthenia gravis.

Deep learning model beats breast density for 5-year breast cancer risk, informing supplemental screening decisions and personalized care.

Deborah Doroshow, MD, PhD, blends oncology and history of medicine to guide cancer care, emphasizing communication, trust, and health equity.

Epcoritamab added to R2 sharply boosts follicular lymphoma responses, but infection risks and real-world feasibility raise tough treatment decisions.

Nirmatrelvir-ritonavir was most likely to be cost-effective among adults aged 18 to 64 years with comorbidities, particularly those with lung disease or immune disorders.

Real-world data show zanubrutinib cuts atrial fibrillation, major bleeding, and mortality versus ibrutinib in B‑cell cancers—guiding safer BTK inhibitor choices.

Their study found cost nudges had minimal effect on clinic selection, as 85% already chose lower-cost tiers, suggesting tiered benefit design works.

Once-feared disease markers are losing their sting as targeted therapies reshape the landscape of ALL, Emily K. Curran, MD, told AJMC.

Patients with late-onset multiple sclerosis are less likely to receive high-efficacy disease-modifying therapies than younger patients.

BCBSNC Foundation president Colleen Briggs, MBA, outlines youth mental health, health through food, and care access priorities, then reflects on the next 25 years.

The POSITIVE study's 2-year real-world data confirm that tildrakizumab drives near-total skin clearance and sustained improvement in difficult-to-treat areas, lending important practical validity to the phase 3 trial results.

Panretinal laser photocoagulation was found to be inferior when compared with brolucizumab in patients with proliferative diabetic retinopathy.

Muhammad Bilal Abid, MD, discusses COVID prevention gaps, monoclonal antibodies, and infection risk in immunocompromised patients with CLL.